Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) EPS (Weighted Average and Diluted) (2022 - 2025)

Corvus Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$0.15 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.15 for Q4 2025, up 6.25% from a year ago — trailing twelve months through Dec 2025 was -$0.5 (up 47.37% YoY), and the annual figure for FY2025 was -$0.53, up 48.04%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.15 at Corvus Pharmaceuticals, down from -$0.12 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for CRVS hit a ceiling of -$0.07 in Q2 2024 and a floor of -$0.6 in Q3 2024.
  • Median EPS (Weighted Average and Diluted) over the past 4 years was -$0.15 (2023), compared with a mean of -$0.18.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 400.0% in 2024 and later surged 80.0% in 2025.
  • Corvus Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.21 in 2022, then surged by 38.1% to -$0.13 in 2023, then dropped by 23.08% to -$0.16 in 2024, then increased by 6.25% to -$0.15 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.15 (Q4 2025), -$0.12 (Q3 2025), and -$0.1 (Q2 2025) per Business Quant data.